Cargando…

Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data

Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced partial protection against clinical malaria in infants and children; given the high burden of the disease it is currently considered for use in malaria endemic countries. To inform adoption decisions th...

Descripción completa

Detalles Bibliográficos
Autores principales: Galactionova, Katya, Bertram, Melanie, Lauer, Jeremy, Tediosi, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357730/
https://www.ncbi.nlm.nih.gov/pubmed/26518406
http://dx.doi.org/10.1016/j.vaccine.2015.10.079
_version_ 1782516090971095040
author Galactionova, Katya
Bertram, Melanie
Lauer, Jeremy
Tediosi, Fabrizio
author_facet Galactionova, Katya
Bertram, Melanie
Lauer, Jeremy
Tediosi, Fabrizio
author_sort Galactionova, Katya
collection PubMed
description Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced partial protection against clinical malaria in infants and children; given the high burden of the disease it is currently considered for use in malaria endemic countries. To inform adoption decisions the paper proposes a generalizable methodology to estimate the cost of vaccine introduction using routinely collected and publicly available data from the cMYP, UNICEF, and WHO-CHOICE. Costing is carried out around a set of generic activities, assumptions, and inputs for delivery of immunization services adapted to a given country and deployment modality to capture among other factors the structure of the EPI program, distribution model, geography, and demographics particular to the setting. The methodology is applied to estimate the cost of RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda. At an assumed vaccine price of $5 per dose and given our assumptions on coverage and deployment strategy, we estimate total economic program costs for a 6–9 months cohort within $23.11–$28.28 per fully vaccinated child across the 6 countries. Net of procurement, costs at country level are substantial; for instance in Tanzania these could add as much as $4.2 million per year or an additional $2.4 per infant depending on the level of spare capacity in the system. Differences in cost of vaccine introduction across countries are primarily driven by differences in cost of labour. Overall estimates generated with the methodology result in costs within the ranges reported for other new vaccines introduced in SSA and capture multiple sources of heterogeneity in costs across countries. Further validation with data from field trials will support use of the methodology while also serving as a validation for cMYP and WHO-CHOICE as resources for costing health interventions in the region.
format Online
Article
Text
id pubmed-5357730
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-53577302017-03-28 Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data Galactionova, Katya Bertram, Melanie Lauer, Jeremy Tediosi, Fabrizio Vaccine Article Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced partial protection against clinical malaria in infants and children; given the high burden of the disease it is currently considered for use in malaria endemic countries. To inform adoption decisions the paper proposes a generalizable methodology to estimate the cost of vaccine introduction using routinely collected and publicly available data from the cMYP, UNICEF, and WHO-CHOICE. Costing is carried out around a set of generic activities, assumptions, and inputs for delivery of immunization services adapted to a given country and deployment modality to capture among other factors the structure of the EPI program, distribution model, geography, and demographics particular to the setting. The methodology is applied to estimate the cost of RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda. At an assumed vaccine price of $5 per dose and given our assumptions on coverage and deployment strategy, we estimate total economic program costs for a 6–9 months cohort within $23.11–$28.28 per fully vaccinated child across the 6 countries. Net of procurement, costs at country level are substantial; for instance in Tanzania these could add as much as $4.2 million per year or an additional $2.4 per infant depending on the level of spare capacity in the system. Differences in cost of vaccine introduction across countries are primarily driven by differences in cost of labour. Overall estimates generated with the methodology result in costs within the ranges reported for other new vaccines introduced in SSA and capture multiple sources of heterogeneity in costs across countries. Further validation with data from field trials will support use of the methodology while also serving as a validation for cMYP and WHO-CHOICE as resources for costing health interventions in the region. Elsevier Science 2015-11-27 /pmc/articles/PMC5357730/ /pubmed/26518406 http://dx.doi.org/10.1016/j.vaccine.2015.10.079 Text en © 2015 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Galactionova, Katya
Bertram, Melanie
Lauer, Jeremy
Tediosi, Fabrizio
Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
title Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
title_full Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
title_fullStr Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
title_full_unstemmed Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
title_short Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data
title_sort costing rts,s introduction in burkina faso, ghana, kenya, senegal, tanzania, and uganda: a generalizable approach drawing on publicly available data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357730/
https://www.ncbi.nlm.nih.gov/pubmed/26518406
http://dx.doi.org/10.1016/j.vaccine.2015.10.079
work_keys_str_mv AT galactionovakatya costingrtssintroductioninburkinafasoghanakenyasenegaltanzaniaandugandaageneralizableapproachdrawingonpubliclyavailabledata
AT bertrammelanie costingrtssintroductioninburkinafasoghanakenyasenegaltanzaniaandugandaageneralizableapproachdrawingonpubliclyavailabledata
AT lauerjeremy costingrtssintroductioninburkinafasoghanakenyasenegaltanzaniaandugandaageneralizableapproachdrawingonpubliclyavailabledata
AT tediosifabrizio costingrtssintroductioninburkinafasoghanakenyasenegaltanzaniaandugandaageneralizableapproachdrawingonpubliclyavailabledata